Next we depleted AURKA in four additional NSCLC lines, two SMARCA4 mutant and two SMARCA4 wild-type, which were previously tested with siRNAs against TPX2. We observed that SMARCA4 mutant lines had significant decrease in cell growth or survival when AURKA was depleted, whereas SMARCA4 wild-type lines were insensitive (Fig. 3e). Here, TPX2 is linked to non-small cell lung carcinoma.